Phentermine with topiramate for the treatment of obesity and overweight
Following on from information provided to NICE by the company in November 2011, the appraisal of Phentermine with topiramate for the treatment of obesity and overweight [ID543] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
Referral date 01 July 2012
Topic area
  • Endocrine, nutritional and metabolic
  • Public health
  • Therapeutic procedures

Provisional Schedule

Closing date for invited submissions / evidence submission: 14 November 2012
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: Andrew Dillon
Project manager: Kate Moore
Technical Lead: Pilar Pinilla-Dominguez

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in November 2011, the appraisal of Phentermine with topiramate for the treatment of obesity and overweight [ID543] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in November 2011, the appraisal of Phentermine with topiramate for the treatment of obesity and overweight [ID543] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
29 April 2013

The Department of Health asked the Institute to conduct an appraisal of phentermine with topiramate for the treatment of obesity and overweight and to provide guidance on its use to the NHS in England and Wales.

The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently re-examined its initial negative opinion for phentermine and has confirmed the refusal of the marketing authorisation.

NICE has therefore decided to suspend this appraisal indefinitely.

As this topic has been referred to the Institute we will continue to monitor any developments and will update this webpage if the situation changes.
6 November 2012

Following an update on the regulatory status of this technology which has received a negative CHMP opinion, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the Committee meeting on 27 February 2013 has been cancelled.

For further information on our processes and methods, please see our CHTE processes and methods manual